THU-003 CIRCULATING MICROPARTICLES AND RISKOF PORTALVEIN THROMBOSIS IN PATIENTS WITH LIVER CIRRHOSIS AND HEPATOCELLULAR CARCINOMA A. Zanetto 1 , A. Ferrarese 1 , E. Nadal 1 , I. Bortoluzzi 1 , E. Campello 2 , L. Spiezia 2 , U. Cillo 3 , A. Vitale 3 , F. Farinati 4 , G. Germani 1 , F.P. Russo 1 , P. Simioni 2 , P. Burra 1 , M. Senzolo 1 . 1 Surgery, Oncology and Gastroenterology, Multivisceral Transplant Unit; 2 Medicine, Vth Chair of Internal Medicine; 3 Surgery, Oncology and Gastroenterology, Hepatobiliary Surgery and Liver Transplantation Unit; 4 Surgery, Oncology and Gastroenterology, Gastroenterology, Padua, Italy E-mail: alberto.zanetto@yahoo.it Background and Aims: Studies which explore the hypercoagulable state associated with hepatocellular carcinoma (HCC) and its correlation with the risk of portal vein thrombosis (PVT) in patients with liver cirrhosis are lacking. The aim of the present study was to investigate the presence of circulating microparticles (MP) in cirrhotic patients with and without HCC as well as to evaluate the possible role of MP as risk factor for PVT development. Methods: Cirrhotic patients with and without HCC were prospectivelyenrolled in the study. Plasma levels of annexin V-MP, endothelial-, platelet- and leukocyte-derived-MP, tissue factor- bearing MP (TF + MP) and thrombomodulin-bearing MP (TM+MP) were measured by cytoflowrimetry. During follow-up, PVTonset in both patients with and without HCC was recorded. Fifty healthy subjects were enrolled as controls. Results: Seventy-six cirrhotics of whom 41 with HCC were enrolled. HCC patients showed significantly higher plasma levels of annexin V- MP [3960 (2442–4533) MP/μL], E-selectin-MP [1251 (1062–2113) MP/μL], platelet-derived MP [1064 (369–2197) MP/μL], leukocyte- derived MP [1074 (644–1326) MP/μL], TF+MP [102 (71–145) MP/μL] and TM + MP [132 (113–159) MP/μL] than patients without HCC [1664 (1354–2435) MP/μL, p < 0.001; 480 (327–594) MP/μL, p < 0.001; 537 (218–865) MP/μL, p < 0.005; 327 (116–772) MP/μL, p < 0.001; 50 (36– 56) MP/μL, p < 0.001 and 95 (42–517) MP/μL, p < 0.05], respectively. Cirrhotic patients without HCC showed significantly higher levels of annexin V-MP, E-selectin-MP, platelet-derived MP, leukocyte-derived MP, and TM+MP compared to healthy controls [1814 (781–2126) MP/ μL] p < 0.01, 146 (117–230) MP/μL p < 0.001, 345 (228–534) MP/μL p = 0.02, 74 (55–161) MP/μL < 0.001, and 40 (34–83) MP/μL p < 0.001, respectively. One-year incidence of PVT was 24.4% (10/41) and 11.4% (4/35) in HCC and non-HCC patients, respectively (OR: 2.5; 95%, CI 0.70–8.83). Levels of annexin V MP and endothelial-derived MP were statistically higher in HCC patients who later developed PVT during follow-up than in HCC patients who did not. Conclusions: The “degree” of hypercoagulabity increases from cirrhosis alone to cirrhosis with HCC. Patients with HCC demonstrate a prothrombotic hemostatic balance resulting in an increased risk of PVT development. Hypercoagulability as assessed by circulating plasma MP levels may contribute to the PVToccurrence. THU-004 WHOLE BLOOD COAGULATION TESTS ARE NOT EQUALLY ABLE TO DETECT HAEMOSTATIC PROTHROMBOTIC ALTERATIONS IN PATIENTS WITH LIVER CIRRHOSIS AND HEPATOCELLULAR CARCINOMA: ROTATIONAL THROMBOELASTOMETRY VERSUS THROMBINGENERATION TEST A. Zanetto 1 , A. Ferrarese 1 , E. Nadal 1 , I. Bortoluzzi 1 , E. Campello 2 , L. Spiezia 2 , U. Cillo 3 , A. Vitale 3 , F. Farinati 4 , G. Germani 1 , F.P. Russo 1 , S. Gavasso 2 , P. Simioni 2 , P. Burra 1 , M. Senzolo 1 . 1 Surgery, Oncology and Gastroenterology, Multivisceral Transplant Unit; 2 Medicine, Vth Chair of Internal Medicine; 3 Surgery, Oncology and Gastroenterology, Hepatobiliary Surgery and Liver Transplantation Unit; 4 Surgery, Oncology and Gastroenterology, Gastroenterology, Padua, Italy E-mail: alberto.zanetto@yahoo.it Background and Aims: Neoplasms are considered as one of the main cause of acquired thrombophilia but studies that explore the coagulation imbalance induced by Hepatocellular Carcinoma (HCC) in liver cirrhosis are lacking. Aim of the present study was to evaluate the thrombophilic role of HCC in patients with liver cirrhosis. Methods: Cirrhotic patients with and without HCC were enrolled in the study and underwent rotational thromboelastometry (ROTEM), platelet count, determination of levels of pro and anticoagulation factors and thrombin generation test [with and without trombomodulin (TM)]. Results: 76 cirrhotics, of whom 41 with HCC, were included. Volume of active HCC was >5 cm 3 in 18 patients. Levels of pro and anticoagulation factors were similar between patients with and without HCC, but fibrinogen was increased in HCC patients with vital tumor volume >5 cm 3 compared to those with <5 cm 3 HCC bulk (348.72 mg/dL± 124.06 mg/dL vs 237.64 mg/dL ± 99.18 mg/dL) and to cirrhotics without HCC (260.57 mg/dL ± 126.07 mg/dL) (p = 0.006). Platelet count was significantly increased in HCC patients compared to non-HCC patients (125.41/mL ± 67.88/mL vs 86.89/mL ± 54.07/mL; p = 0.04), and this was especially true within the Child Class A (152.6/ mL ± 66.14/mL vs 92/mL ± 46.73/mL; p = 0.03). ROTEM demonstrated a significantly lower clotting time and maximum clot formation in HCC patients compared to non-HCC. Endogenous thrombin potential, peak time, lag time and ETP ratio of TG (with and without TM) were not different between patients with and without HCC, even when a sub-analysis accordingly to Child Class was performed. No difference in TG parameters was found between patients with HCC> and <5 cm 3 . Correlation between ETP with and without TM and fibrinogen plasmatic level was found both in HCC and non- HCC patients (r= 0.730, p = 0.001 and r = 0.657, p = 0.001; r = 0.710, p = 0.002 and r = 0.720, p = 0.005, respectively). Conclusions: The unstable hemostatic balance in cirrhotic patients can easily tip towards hypercoagulability. ROTEM test seemsto be a sensitive method that is able to measure hypercoagulability, which would otherwise be undetected by routine laboratory testing or by dosing plasmatic levels of pro and anticoagulation factors. Thrombin generation test failed to detect any differences between HCC and non-HCC patients. THU-005 SUSTAINED VIROLOGICAL RESPONSES (SVR) OF 97% IN GENOTYPE 2 (GT-2) PATIENTS WITH F3/4 STAGE OF FIBROSIS TREATEDWITH SOFOSBUVIR (SOF) AND WEIGHT-BASED RIBAVIRIN (RBV): A REAL LIFE, SINGLE CENTRE EXPERIENCE A. Mangia 1 , A. Arleo 1 , V. Piazzolla 1 , R. Santoro 1 , D. Petruzzellis 1 , M. Miscio 1 , M.M. Squillante 1 . 1 Liver Unit, Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy E-mail: a.mangia@tin.it Background and Aims: The currently approved treatment for pts with GT-2 infection is the combination of SOF/RBV. In US, comparing real life to phase III studies, reduced SVR rates were shown. Moreover, although EASL guidelines advice, as maximum, a duration of 20 wks, it is debated whether treatment should be further extended to 24 wks, in order to prevent relapse. In a cohort of HCV GT-2 patients treated from January 2015, according to DAA approval in Italy, efficacy results of SOF/RBV were evaluated. Methods: 215 patients with GT-2 and Metavir F3/4 fibrosis stage were eligible to treatment; 20 RBV ineligiblewere excluded, all the others received SOF/RBV for 12 or 20 wks according to absence/presence of cirrhosis. Efficacy was evaluated based on HCV RNA at post-treatment wk 12 by ABBOTT HCVRNA, LLQ<12 IU/mL. This preliminaryanalysis includes 143 patients who already completed this assessment. Final results, including 52 pts on treatment, will be available for presentation. Results: The majority of pts were female (53.2%),105 non-CC (74%); median age was 65.8 yrs (18–86); mean BMI 25.1. Three pts had Non-Hodgkin lymphoma and were excluded from this analysis. Of 140 pts, half had cirrhosis; 58.4% were naïve. Co-morbidities including diabetes, blood hypertension, hemoglobinopathies and POSTER PRESENTATIONS S246 Journal of Hepatology 2016 vol. 64 | S213–S424